drugset / Trial / NCT04156178
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies
Phase 0
Unknown
12 enrolled
iCell Gene Therapeutics
Chengdu Military General Hospital · collabPeking University Shenzhen Hospital · collabiCAR Bio Therapeutics Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD20-CD19 cCAR in patients with relapsed and/or refractory B cell malignancies.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2020-09-30
- Completion
- 2020-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD20-CD19 cCAR T cells | Cell therapy | — | Intravenous |